116 related articles for article (PubMed ID: 26507218)
1. Acid Mediated Ring Closing Metathesis: A Powerful Synthetic Tool Enabling the Synthesis of Clinical Stage Kinase Inhibitors.
William AD; Lee AC
Chimia (Aarau); 2015; 69(3):142-5. PubMed ID: 26507218
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
3. Kinetically E-selective macrocyclic ring-closing metathesis.
Shen X; Nguyen TT; Koh MJ; Xu D; Speed AW; Schrock RR; Hoveyda AH
Nature; 2017 Jan; 541(7637):380-385. PubMed ID: 28068669
[TBL] [Abstract][Full Text] [Related]
4. The role of pacritinib in the management of myelofibrosis.
Duong VH; Komrokji RS
Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
[TBL] [Abstract][Full Text] [Related]
6. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
7. Total syntheses of (-)-huperzine Q and (+)-lycopladines B and C.
Hong B; Li H; Wu J; Zhang J; Lei X
Angew Chem Int Ed Engl; 2015 Jan; 54(3):1011-5. PubMed ID: 25358669
[TBL] [Abstract][Full Text] [Related]
8. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
[TBL] [Abstract][Full Text] [Related]
10. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Jain T; Mesa R
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
[TBL] [Abstract][Full Text] [Related]
11. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
12. Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
Passamonti F
Leuk Res; 2014 Mar; 38(3):290-1. PubMed ID: 24444869
[No Abstract] [Full Text] [Related]
13. Stereoselective synthesis of the phorboxazole A macrolide by ring-closing metathesis.
Wang B; Forsyth CJ
Org Lett; 2006 Nov; 8(23):5223-6. PubMed ID: 17078683
[TBL] [Abstract][Full Text] [Related]
14. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
15. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma.
Mullally A; Ebert BL
J Clin Oncol; 2012 Nov; 30(33):4168-70. PubMed ID: 22965959
[No Abstract] [Full Text] [Related]
16. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Nagaraj H; Williams M; Wang H; Lee A; Sun E; Teo EL; Tan E; Goh KC; Dymock B
J Mol Model; 2013 Jan; 19(1):119-30. PubMed ID: 22820730
[TBL] [Abstract][Full Text] [Related]
17. Construction of the cyclophane core of the hirsutellones via a RCM strategy.
Huang M; Song L; Liu B
Org Lett; 2010 Jun; 12(11):2504-7. PubMed ID: 20446677
[TBL] [Abstract][Full Text] [Related]
18. Exceedingly Efficient Synthesis of (±)-Grandifloracin and Acylated Analogues.
Bergner M; Duquette DC; Chio L; Stoltz BM
Org Lett; 2015 Jun; 17(12):3008-10. PubMed ID: 26060887
[TBL] [Abstract][Full Text] [Related]
19. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
20. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
[Next] [New Search]
